- Home
- AUPH vs MFIC Comparison
AUPH vs MFIC Comparison
Compare AUPH & MFIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- MFIC
- Stock Information
- Founded
- AUPH 1993
- MFIC 2004
- Country
- AUPH Canada
- MFIC United States
- Employees
- AUPH N/A
- MFIC N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- MFIC Finance/Investors Services
- Sector
- AUPH Health Care
- MFIC Finance
- Exchange
- AUPH Nasdaq
- MFIC Nasdaq
- Market Cap
- AUPH 1.1B
- MFIC 1.1B
- IPO Year
- AUPH 1999
- MFIC 2004
- Fundamental
- Price
- AUPH $8.86
- MFIC $13.16
- Analyst Decision
- AUPH Strong Buy
- MFIC Buy
- Analyst Count
- AUPH 2
- MFIC 5
- Target Price
- AUPH $11.50
- MFIC $13.60
- AVG Volume (30 Days)
- AUPH 2.0M
- MFIC 420.5K
- Earning Date
- AUPH 07-31-2025
- MFIC 08-11-2025
- Dividend Yield
- AUPH N/A
- MFIC 11.67%
- EPS Growth
- AUPH N/A
- MFIC N/A
- EPS
- AUPH 0.27
- MFIC 1.22
- Revenue
- AUPH $247,295,000.00
- MFIC $312,149,000.00
- Revenue This Year
- AUPH $12.15
- MFIC $9.71
- Revenue Next Year
- AUPH $18.31
- MFIC $0.21
- P/E Ratio
- AUPH $33.08
- MFIC $10.80
- Revenue Growth
- AUPH 29.20
- MFIC 12.66
- 52 Week Low
- AUPH $5.20
- MFIC $10.18
- 52 Week High
- AUPH $10.67
- MFIC $15.70
- Technical
- Relative Strength Index (RSI)
- AUPH 64.10
- MFIC 67.69
- Support Level
- AUPH $7.36
- MFIC $12.44
- Resistance Level
- AUPH $9.10
- MFIC $12.89
- Average True Range (ATR)
- AUPH 0.44
- MFIC 0.21
- MACD
- AUPH 0.10
- MFIC 0.07
- Stochastic Oscillator
- AUPH 89.53
- MFIC 93.75
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About MFIC MidCap Financial Investment Corporation
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.